Sensei Biotherapeutics Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sensei Biotherapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Sensei Biotherapeutics stock.
View analyst ratings for Sensei Biotherapeutics or view top-rated stocks.

Wall Street analysts have given Sensei Biotherapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Sensei Biotherapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Sensei Biotherapeutics is scheduled to release its next quarterly earnings announcement on Thursday, June 24th 2021.
View our earnings forecast for Sensei Biotherapeutics.

4 equities research analysts have issued 1 year target prices for Sensei Biotherapeutics' stock. Their forecasts range from $25.00 to $36.00. On average, they anticipate Sensei Biotherapeutics' share price to reach $29.50 in the next twelve months. This suggests a possible upside of 103.4% from the stock's current price.
View analysts' price targets for Sensei Biotherapeutics or view top-rated stocks among Wall Street analysts.

Some companies that are related to Sensei Biotherapeutics include ImmunityBio (IBRX), BioAtla (BCAB), Cullinan Oncology (CGEM), Cricut (EWTX), Immunocore (IMCR), Kinnate Biopharma (KNTE), Trillium Therapeutics (TRIL), Nurix Therapeutics (NRIX), Silverback Therapeutics (SBTX), Concordia International (CXR), Vor Biopharma (VOR), PureTech Health (PRTC), Connect Biopharma Holdings Limited American Depositary Shares (CNTB), Pharvaris B.V. (PHVS) and 4D Molecular Therapeutics (FDMT).
View all of SNSE's competitors.

(SNSE) raised $100 million in an initial public offering on Friday, February 5th 2021. The company issued 5,900,000 shares at $16.00-$18.00 per share. Citigroup, Piper Sandler, Berenberg and Oppenheimer & Co. acted as the underwriters for the IPO.

Sensei Biotherapeutics trades on the NASDAQ under the ticker symbol "SNSE."

Sensei Biotherapeutics' lock-up period expires on Tuesday, August 3rd. Sensei Biotherapeutics had issued 7,000,052 shares in its public offering on February 4th. The total size of the offering was $133,000,988 based on an initial share price of $19.00. After the expiration of the company's lock-up period, company insiders and major shareholders will be able to sell their shares of the company.

Shares of SNSE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SNSE stock can currently be purchased for approximately $14.50.

Sensei Biotherapeutics has a market capitalization of $443.53 million.

The official website for Sensei Biotherapeutics is www.senseibio.com.

The company can be reached via phone at 240 243 8000.